Shenzhen-based Innorna Co., Ltd has announced that it has received approval from the National Medical Products Administration (NMPA) to commence clinical trials for its proprietary IN001, a novel mRNA vaccine designed to combat herpes zoster. This marks a significant milestone for the company, as IN001 is the first mRNA-based herpes zoster vaccine to be approved for clinical trials in China, following similar approvals for Moderna and Pfizer/BioNTech vaccines globally. The drug has already been granted clinical trial approval in the US in September 2023 and is currently undergoing a Phase I study in healthy subjects overseas. IN001 is expected to offer a potentially safer and more effective treatment option for herpes zoster, a disease that predominantly affects individuals aged 50 and above.- Flcube.com
Recent news:
-
Shanghai Designates Backup Suppliers and Specialized Drug Formulations in GY-YD2024-2 Procurement -
Abbott Laboratories' Volt PFA System Receives EU CE Mark for Atrial Fibrillation Treatment -
Alcon Laboratories Acquires Majority Stake in Aurion Biotech to Advance Eye Disease Cell Therapy -
Genmab's Tivdak Approved in Japan for Advanced Cervical Cancer Treatment -
CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline
